MSACL 2019 EU Abstract

Self-Classified Topic Area(s): Microbiology

Quick Pathogen Identification and Antibiogram for the Clinics by MS/MS Proteotyping

Olivier Pible (1), Karen Culotta (1), Guylaine Miotello (1), Virginie Jouffret (1), Laetitia Lecci (2), Olivier Gaillot (2), Nadine Lemaitre (2), Lucia Grenga (1), Jean Armengaud (1)
(1) Li2D, CEA, Bagnols-sur-Cèze, France (2) CHU Lille, France

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Jean Armengaud (Presenter)
CEA

Presenter Bio: Jean Armengaud, PhD, is best known for his work on proteogenomics of bacteria and the characterization of pathogens and environmental organisms. He directs a mass spectrometry research unit located near Avignon in France that is dedicated to proteomics-based identification and quantitation of pathogens and environmentally relevant bacteria.

Relevant Financial Disclosures (within past 24 months)

Committee/Board/Advisory Board MSACL EU

Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above.

Conflict mitigation NOT REQUIRED.

Abstract

Mass spectrometry is a powerful tool to identify pathogens. However some issues such as mixture handling are usually beyond reach of whole-cell MALDI-TOF approaches. We developed a tandem mass spectrometry approach which addresses without a priori any kind of isolates but also more complex samples such as mixtures of organisms. Based on the analysis of the whole set of identified peptides from the sample, a phylogenetic information is quickly processed and presented in a format easily accessible for the clinician. An in-house developed microbiota reference standard comprising 24 different microorganisms was used for optimizing parameters for data acquisition by tandem mass spectrometry and data processing. Furthermore, the peptide signal is automatically search against a protein sequence database listing all the proteins involved in antibiotic resistances. This allows obtaining a quick pathogen identification and proposing an in silico antibiogram. This pipeline has been challenged with hundreds of clinical samples and resulted very robust. This work paves the way to wide proteotyping applications in the clinical lab.